The U.S. biotech sector is experiencing significant growth, fueled by groundbreaking advancements in genetic therapies, personalized medicine, and immunotherapy. As the industry continues to push the boundaries of medical innovation, companies driving breakthroughs in gene therapy and genetic treatments are gaining attention.
Therefore, solid biotech stocks Gilead Sciences, Inc. (GILD), Vertex Pharmaceuticals Incorporated (VRTX), and Regeneron Pharmaceuticals, Inc. (REGN) coulc be ideal buys.
